Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts | Zendy

Ngoc-Quynh Chu | Zendy; Rong Liu | Zendy; Aaron H. Colby | Zendy; Claire de Forcrand | Zendy; Robert F. Padera | Zendy; Mark W. Grinstaff | Zendy; Yolonda L. Colson | Zendy

Open Access

Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts

Author(s) -

Ngoc-Quynh Chu,

Rong Liu,

Aaron H. Colby,

Claire de Forcrand,

Robert F. Padera,

Mark W. Grinstaff,

Yolonda L. Colson

Publication year - 2020

Publication title -

journal of thoracic and cardiovascular surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.458

H-Index - 192

eISSN - 1085-8687

pISSN - 0022-5223

DOI - 10.1016/j.jtcvs.2019.12.076

Subject(s) - paclitaxel , medicine , mesothelioma , pleural disease , in vivo , chemotherapy , pleural cavity , cancer research , pathology , oncology , surgery , respiratory disease , biology , lung , microbiology and biotechnology

Malignant pleural mesothelioma is a lethal malignancy with poor survival and high local recurrence rates despite multimodal therapy with cytoreduction and chemoradiation. We evaluated the antitumor efficacy of a paclitaxel-loaded pH-responsive expansile nanoparticle (PTX-eNP) in 2 clinically relevant murine xenograft models of malignant pleural mesothelioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research